Choosing Between Gene Editing and Orphan Disease Treatments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Source: Fool
- Financial Performance Comparison: Intellia Therapeutics reported approximately $67.7 million in revenue for FY 2025, reflecting a nearly 17% year-over-year growth, yet it faced a substantial net loss of $412.7 million, highlighting the high-risk, high-reward nature of gene editing.
- Product Approval and Market Outlook: Omeros transitioned to a commercial-stage company with the FDA's approval of Yartemlea in late 2025, projecting sales of $68.9 million in 2026, indicating strong market demand for its orphan disease treatment.
- Risks and Challenges: Intellia faces significant risks related to clinical development and regulatory hurdles, particularly with a key trial on hold due to a patient death, which could delay approvals, while Omeros's financial viability heavily depends on the market acceptance of Yartemlea, where any failure could materially impact its operations.
- Market Valuation Discrepancies: While Intellia is not forecasted to have earnings, its price-to-sales ratio of 28.5 contrasts sharply with Omeros's 74.2, reflecting a higher market expectation for the latter and investor confidence in Omeros's future profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 15.200
Low
4.00
Averages
16.50
High
54.00
Current: 15.200
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Choices in Gene Editing and Rare Disease Treatments
- Strategic Partnership Advantage: Intellia Therapeutics' deep collaboration with Regeneron accelerates the development of CRISPR gene editing therapies, achieving approximately $67.7 million in revenue for FY 2025, reflecting a nearly 17% year-over-year growth, despite a net loss of about $412.7 million, highlighting both potential and challenges in the high-risk biotech sector.
- Commercial Transition: Omeros has entered the commercial stage with FDA approval of Yartemlea in 2025, reporting no revenue for the fiscal year, yet its partnership with Novo Nordisk offers potential milestone payments and royalties, essential for its long-term revenue strategy.
- Clinical Development Risks: Intellia's nex-z trial is on hold due to a patient death, potentially delaying approvals, while another trial's clinical hold was lifted in January 2026, illustrating the challenges posed by complex intellectual property litigation.
- Market Outlook Comparison: Omeros reported $9.89 million in Yartemlea sales in Q1 2026, with expectations to double revenue in 2027, while Intellia's promising gene editing technology faces higher investment risks due to its early-stage pipeline and ongoing losses.
See More
Choosing Between Gene Editing and Orphan Disease Treatments
- Financial Performance Comparison: Intellia Therapeutics reported approximately $67.7 million in revenue for FY 2025, reflecting a nearly 17% year-over-year growth, yet it faced a substantial net loss of $412.7 million, highlighting the high-risk, high-reward nature of gene editing.
- Product Approval and Market Outlook: Omeros transitioned to a commercial-stage company with the FDA's approval of Yartemlea in late 2025, projecting sales of $68.9 million in 2026, indicating strong market demand for its orphan disease treatment.
- Risks and Challenges: Intellia faces significant risks related to clinical development and regulatory hurdles, particularly with a key trial on hold due to a patient death, which could delay approvals, while Omeros's financial viability heavily depends on the market acceptance of Yartemlea, where any failure could materially impact its operations.
- Market Valuation Discrepancies: While Intellia is not forecasted to have earnings, its price-to-sales ratio of 28.5 contrasts sharply with Omeros's 74.2, reflecting a higher market expectation for the latter and investor confidence in Omeros's future profitability.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Intellia Therapeutics Shows Significant Progress, Stock Up 58%
- Clinical Trial Resumption: Intellia Therapeutics successfully resumed its clinical trials after overcoming a temporary hold by the FDA on two phase 3 studies, resulting in a 58% increase in stock price year-to-date, reflecting market confidence in its future potential.
- Gene Editing Therapy Effectiveness: In a recent phase 3 clinical trial, patients treated with lonvo-z experienced an 87% reduction in attacks, with 62% completely attack-free, indicating significant efficacy in treating hereditary angioedema and potential to become the standard of care.
- Substantial Market Opportunity: Although the hereditary angioedema patient population is only about 7,000 in the U.S., lonvo-z could represent a market size of $7 billion, with estimated lifetime sales of $3.5 billion at a 50% penetration rate, highlighting its commercial appeal.
- Future Growth Potential: Intellia is also developing nex-z for transthyretin amyloidosis, with a patient population of 250,000 to 500,000 globally; successful clinical trials could further enhance the company's stock price and market position.
See More
Intellia Therapeutics' Drug Phase 3 Trial Success
- Clinical Trial Success: Intellia Therapeutics' lonvo-z achieved positive results in a phase 3 trial for hereditary angioedema, with an 87% reduction in attacks after a single infusion, demonstrating the drug's efficacy and market appeal.
- Market Potential Assessment: Although the patient population for lonvo-z is only about 7,000, with a treatment cost of $1 million, its total addressable market in the U.S. could reach $7 billion, suggesting a potential lifetime sales of $3.5 billion, reflecting significant commercial value.
- Regulatory Progress: Intellia has begun submitting its application to the FDA for lonvo-z approval, aiming for a launch in the first half of 2027, which could establish it as the standard of care for hereditary angioedema and enhance the company's market position.
- Future Development Risks: Despite lonvo-z's promising outlook, Intellia faces clinical and regulatory risks, particularly with its other candidate nex-z, which has been put on clinical hold by the FDA, necessitating cautious evaluation of potential volatility by investors.
See More
Intellia Therapeutics Shows Significant Progress, Stock Up 58%
- Clinical Trial Resumption: Intellia Therapeutics successfully resumed its clinical trials after the FDA placed two phase 3 studies on hold, resulting in a 58% increase in stock price year-to-date, reflecting market confidence in its future potential.
- Gene Editing Therapy Progress: On April 27, Intellia announced phase 3 trial results for lonvo-z, showing an 87% reduction in attacks and 62% of patients completely free of attacks after a single infusion, indicating the therapy's potential to become the standard of care for HAE.
- Market Opportunity Assessment: Although there are only about 7,000 HAE patients, lonvo-z could represent a market opportunity of $7 billion, with an estimated lifetime sales of $3.5 billion assuming a 50% penetration rate, highlighting its commercial value.
- Future Development Prospects: Intellia is also developing nex-z for treating ATTR, with a global patient population of 250,000 to 500,000; if clinical trials succeed, it could significantly enhance the company's outlook and drive further stock price increases.
See More
Investment Choices in Gene Editing and Rare Disease Treatments
- Strategic Partnership Advantage: Intellia Therapeutics' deep collaboration with Regeneron accelerates the development of CRISPR gene editing therapies, achieving approximately $67.7 million in revenue for FY 2025, reflecting a nearly 17% year-over-year growth, despite a net loss of about $412.7 million, highlighting both potential and challenges in the high-risk biotech sector.
- Commercial Transition: Omeros has entered the commercial stage with FDA approval of Yartemlea in 2025, reporting no revenue for the fiscal year, yet its partnership with Novo Nordisk offers potential milestone payments and royalties, essential for its long-term revenue strategy.
- Clinical Development Risks: Intellia's nex-z trial is on hold due to a patient death, potentially delaying approvals, while another trial's clinical hold was lifted in January 2026, illustrating the challenges posed by complex intellectual property litigation.
- Market Outlook Comparison: Omeros reported $9.89 million in Yartemlea sales in Q1 2026, with expectations to double revenue in 2027, while Intellia's promising gene editing technology faces higher investment risks due to its early-stage pipeline and ongoing losses.
See More
Choosing Between Gene Editing and Orphan Disease Treatments
- Financial Performance Comparison: Intellia Therapeutics reported approximately $67.7 million in revenue for FY 2025, reflecting a nearly 17% year-over-year growth, yet it faced a substantial net loss of $412.7 million, highlighting the high-risk, high-reward nature of gene editing.
- Product Approval and Market Outlook: Omeros transitioned to a commercial-stage company with the FDA's approval of Yartemlea in late 2025, projecting sales of $68.9 million in 2026, indicating strong market demand for its orphan disease treatment.
- Risks and Challenges: Intellia faces significant risks related to clinical development and regulatory hurdles, particularly with a key trial on hold due to a patient death, which could delay approvals, while Omeros's financial viability heavily depends on the market acceptance of Yartemlea, where any failure could materially impact its operations.
- Market Valuation Discrepancies: While Intellia is not forecasted to have earnings, its price-to-sales ratio of 28.5 contrasts sharply with Omeros's 74.2, reflecting a higher market expectation for the latter and investor confidence in Omeros's future profitability.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Intellia Therapeutics Shows Significant Progress, Stock Up 58%
- Clinical Trial Resumption: Intellia Therapeutics successfully resumed its clinical trials after overcoming a temporary hold by the FDA on two phase 3 studies, resulting in a 58% increase in stock price year-to-date, reflecting market confidence in its future potential.
- Gene Editing Therapy Effectiveness: In a recent phase 3 clinical trial, patients treated with lonvo-z experienced an 87% reduction in attacks, with 62% completely attack-free, indicating significant efficacy in treating hereditary angioedema and potential to become the standard of care.
- Substantial Market Opportunity: Although the hereditary angioedema patient population is only about 7,000 in the U.S., lonvo-z could represent a market size of $7 billion, with estimated lifetime sales of $3.5 billion at a 50% penetration rate, highlighting its commercial appeal.
- Future Growth Potential: Intellia is also developing nex-z for transthyretin amyloidosis, with a patient population of 250,000 to 500,000 globally; successful clinical trials could further enhance the company's stock price and market position.
See More
Intellia Therapeutics' Drug Phase 3 Trial Success
- Clinical Trial Success: Intellia Therapeutics' lonvo-z achieved positive results in a phase 3 trial for hereditary angioedema, with an 87% reduction in attacks after a single infusion, demonstrating the drug's efficacy and market appeal.
- Market Potential Assessment: Although the patient population for lonvo-z is only about 7,000, with a treatment cost of $1 million, its total addressable market in the U.S. could reach $7 billion, suggesting a potential lifetime sales of $3.5 billion, reflecting significant commercial value.
- Regulatory Progress: Intellia has begun submitting its application to the FDA for lonvo-z approval, aiming for a launch in the first half of 2027, which could establish it as the standard of care for hereditary angioedema and enhance the company's market position.
- Future Development Risks: Despite lonvo-z's promising outlook, Intellia faces clinical and regulatory risks, particularly with its other candidate nex-z, which has been put on clinical hold by the FDA, necessitating cautious evaluation of potential volatility by investors.
See More
Intellia Therapeutics Shows Significant Progress, Stock Up 58%
- Clinical Trial Resumption: Intellia Therapeutics successfully resumed its clinical trials after the FDA placed two phase 3 studies on hold, resulting in a 58% increase in stock price year-to-date, reflecting market confidence in its future potential.
- Gene Editing Therapy Progress: On April 27, Intellia announced phase 3 trial results for lonvo-z, showing an 87% reduction in attacks and 62% of patients completely free of attacks after a single infusion, indicating the therapy's potential to become the standard of care for HAE.
- Market Opportunity Assessment: Although there are only about 7,000 HAE patients, lonvo-z could represent a market opportunity of $7 billion, with an estimated lifetime sales of $3.5 billion assuming a 50% penetration rate, highlighting its commercial value.
- Future Development Prospects: Intellia is also developing nex-z for treating ATTR, with a global patient population of 250,000 to 500,000; if clinical trials succeed, it could significantly enhance the company's outlook and drive further stock price increases.
See More
